TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

new prediction equation. Ann Intern Med 1999;130:461-70.
14A.1 Okhuysen PC. Traveler‘s diarrhea due to intestinal protozoa. Clin Infect Dis 2001;33:110-4.
14A.2 Harhay MO et al. Epidemiology and control of human gastrointestinal parasites in children. Expert
Rev Anti Infect Ther 2010;8:219-34.
14A.3 Lewthwaite P et al. Gastrointestinal parasites in the immunocompromised. Curr Opin Infect Dis
2005;18:427-35.
14A.4 Lean S et al. Management of protozoa-related diarrhea in HIV infection. Expert Rev Anti Infect Ther
2003;1:455-69.
14A.5 Derouin F et al. Treatment of parasitic diarrhea in HIV-infected patients. Expert Rev Anti Infect Ther
2008;6:337-49.
14A.6 Stark D et al. Clinical significance of enteric protozoa in the immunosuppressed human population.
Clin Microbiol Rev 2009;22:634-50.
14A.7 Salles JM et al. Invasive amebiasis: an update on diagnosis and management. Expert Rev Anti Infect
Ther 2007;5:893-901.
14A.8 Haque R et al. Amebiasis. N Engl J Med 2003;348:1565-73.
14A.9 Stanley SL. Amoebiasis. Lancet 2003;361:1025-34.
14A.10 Fotedar R et al. Laboratory diagnostic techniques for Entamoeba species. Clin Microbiol Rev 2007;
20:511-32.
14A.11 Pritt BS et al. Amebiasis. Mayo Clin Proc 2008;83:1154-60.
14A.12 Rossignol JF et al. Nitazoxanide in the treatment of amoebiasis. Trans R Soc Trop Med Hyg 2007;
101:1025-31.
14A.13 Schuster FL et al. Current world status of Balantidium coli. Clin Microbiol Rev 2008;21:626-38.
14A.14 Tan KS. New insights on classification, identification, and clinical relevance of Blastocystis spp. Clin
Microbiol Rev 2008;21:639-65.
14A.15 Moghaddam DD et al. Blastocystis hominis and the evaluation of efficacy of metronidazole and trimethoprim/sulfamethoxazole.
Parasitol Res 2005;96:273-5.
14A.16 Sohail MR et al. Blastocystis hominis and travelers. Travel Med Infect Dis 2005;3:33-8.
14A.17 Stensvold CR et al. Pursuing the clinical significance of Blastocystis. Diagnostic limitations. Trends
Parasitol 2008;25:23-9.
14A.18 Rossignol JF et al. Effect of nitazoxanide in persistent diarrhea and enteritis associated with Blastocystis
hominis. Clin Gastroenterol Hepatol 2005;3:987-91.
14A.19 Davies AP et al. Cryptosporidiosis. Br Med J 2009;339:963-7.
14A.20 Pantenburg B et al. Treatment of cryptosporidiosis. Expert Rev Anti Infect Ther 2009;7:385-91.
14A.21 Hunter PR et al. Health sequelae of human cryptosporidiosis in immunocompetent patients. Clin Infect
Dis 2004;39:504-10.
14A.22 Chen XM et al. Cryptosporidiosis. N Engl J Med 2002;346:1723-31.
14A.23 Smith HV et al. New drugs and treatment for cryptosporidiosis. Curr Opin Infect Dis 2004;17:557-
64.
14A.24 Thompson RC et al. Cryptosporidium and cryptosporidiosis. Adv Parasitol 2005;59:77-158.
14A.25 Armson A et al. A review of chemotherapeutic approaches to the treatment of cryptosporidiosis. Expert
Rev Anti Infect Ther 2003;1:297-305.
14A.26 Cacciò SM et al. Advances in the epidemiology, diagnosis and treatment of cryptosporidiosis. Expert
Rev Anti Infect Ther 2006;4:429-43.
14A.27 Zardi EM et al. Treatment of cryptosporidiosis in immunocompromised hosts still an open question.
Chemotherapy 2005;51:193-6.
14A.28 Hewitt RG et al. Paromomycin: no more effective than placebo for treatment of cryptosporidiosis in
patients with advanced human immunodeficiency virus infection. Clin Infect Dis 2000;31:1084-92.
14A.29 Ortega YR et al. Update on Cyclospora cayetanensis, a foodborne and waterborne parasite. Clin Microbiol
Rev 2010;23:818-34.
14A.30 Verdier RI et al. Trimethoprim-sulfamethoxazole compared with ciprofloxacin for treatment and prophylaxis
of Isospora belli and Cyclospora cayetanensis infection in HIV infected patients. A randomized,
controlled trial. Ann Intern Med 2000;132:885-8.
14A.31 Zimmer SM et al. Efficacy of nitazoxanide for cyclosporiasis in patients with sulfa allergy. Clin Infect
Dis 2007;44:466-7.
14A.32 Stark D et al. A review of the clinical presentation of dientamoebiasis. Am J Trop Med Hyg 2010;82:
614-9.
14A.33 Johnson EH et al. Emerging from obscurity: biological, clinical and diagnostic aspects of Dientamoeba
fragilis. Clin Microbiol Rev 2004;17:553-70.
14A.34 Stark DJ et al. Dientamoebiasis: clinical importance and recent advances. Trends Parasitol 2006;22:
92-6.
14A.35 Vandenberg O et al. Treatment of Dientamoeba fragilis infection with paromomycin. Pediatr Infect
Dis J 2007;26:88-90.
14A.36 Gardner TB et al. Treatment of giardiasis. Clin Microbiol Rev 2001;14:114-28.
14A.37 Nash TE et al. Treatment of patients with refractory giardiasis. Clin Infect Dis 2001;33:22-8.
14A.38 Verdier RI et al. Trimethoprim-sulfamethoxazole compared with ciprofloxacin for treatment and prophylaxis
of Isospora belli and Cyclospora cayetanensis infection in HIV infected patients. A randomized,
controlled trial. Ann Intern Med 2000;132:885-8.
14A.39 Didier ES et al. Therapeutic strategies for human microsporidia infections. Expert Rev Anti Infect
Ther 2005;3:419-34.
14A.40 Mathis A et al. Zoonotic potential of the microsporidia. Clin Microbiol Rev 2005;18:423-45.
14A.41 Didier ES. Microsporidiosis: an emerging and opportunistic infection in humans and animals. Acta
Trop 2005;94:61-76.
14A.42 Groβ U. Treatment of microsporidiosis including albendazole. Parasitol Res 2003;90(suppl. 1):S14-
8.
14A.43 Molina JM et al. Fumagillin treatment of intestinal microsporidiosis. N Engl J Med 2002;346:1963-9.
14A.44 Fayer R. Sarcocystis spp. in humans. Clin Microbiol Rev 2004;17:894-902.
14A.45 Sra KK et al. Treatment of protozoan infections. Dermatol Ther 2004;17:513-6.
14A.46 Walker MD et al. Neuroparasitic infections: cestodes, treamtodes and protozoans. Semin Neurol
2005;25:262-77.
14A.47 Haque R et al. Amebiasis. N Engl J Med 2003;348:1565-73.
14A.48 Visvesvara GS et al. Pathogenic and opportunistic free-living amoebae: Acanthamoeba spp., Balamuthia
mandrillaris, Naegleria fowleri, and Sappinia diploidea. FEMS Immunol Med Microbiol 2007;